's hedge fund Passport Capital has picked up 416,329 shares of
), according to
GuruFocus Real Time Picks
, which increases the size of his holding by 5 percent. After the
purchase, he holds a total of 8,552,929 shares, giving him 8.5
percent ownership of the company.
VIVUS develops new biopharmaceutical treatments for obesity,
diabetes, sleep apnea and sexual health. It currently has two
standout drugs: Qsymia, the first new medication for the
treatment of obesity available in 13 years, and Stendra, for the
treatment of erectile dysfunction.
Qsymia was FDA approved on July 17, 2012 and introduced to the
U.S. market on Sept. 18, 2012, and Stendra received FDA approval
on April 27, 2012.
On Oct. 18, the European Medicines Agency's (EMA) Committee for
Medicinal Products for Human use (
) recommended against VIVUS's Marketing Authorization Application
) for Qsiva in the EU (Qsiva is the brand name for Qsymia in the
EU). The committee had concerns about the drug's potential affect
on the cardiovascular system and nervous system after long-term
use, as well as teratogenic potential and use by patients Qsiva
is not intended for.
Once the company receives regulatory approval for Qsiva and
Spendra in the EU and other countries, it will be poised to enter
into collaboration agreements for the commercialization of the
drugs in the EU and worldwide, and develop other drugs.
In the second quarter ended June 30, VIVUS reported a net loss of
$24 million, or $0.24 per share, compared to a net loss of $16.2
million, or $0.20 per share in the second quarter the previous
year. Net losses increased primarily due to greater expenses for
preparation for the launch of Qsymia.
VIVUS at quarter-end had cash of $310.4 million, compared to
$145.8 million at year-end 2011, with the increase primarily
coming from the $192 million net proceeds it gained in a public
stock offering in March. VIVUS has primarily financed itself
through issuing equity securities since its inception.
Year to date, VIVUS's stock has increased 48 percent. The company
has a market cap of $1.45 billion, a P/B ratio of 5.7, close to a
one-year low, and a P/S ratio of 35.2, close to its one-year low
VIVUS is Burbank's largest long equity position, followed by
Cytec Industries (
), Liberty Interactive Corp. (
), Marathon Petroleum Corp. (
) and Kinder Morgan Inc. (
About GuruFocus Real Time Picks
Real Time Picks
alerts you of the stock purchases and sales that Gurus have made
within the last two days. Follow your favorite Gurus closely with
GuruFocus' Premium Membership. If you are not a Premium Member,
we invite you for a
7-Day Free Trial
.About GuruFocus: GuruFocus.com tracks the stocks picks and
portfolio holdings of the world's best investors. This value
investing site offers stock screeners and valuation tools. And
publishes daily articles tracking the latest moves of the world's
best investors. GuruFocus also provides promising stock ideas in
3 monthly newsletters sent to